Related Experiment Video
Updated: May 23, 2026
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
Published on: July 28, 2010
Lack of diagnostic potential of Dickkopf-1 in colon and rectum cancers
Hilal Oguz Soydinc1, Derya Duranyildiz, Hakan Camlica
1Istanbul University Oncology Institute, Istanbul, Turkey. hilaloguz@yahoo.com
Abstract:
The Wnt/b-catenin signalling pathway plays crucial roles in development and its aberrant activation is an initial and crucial event in the majority of colon cancers. The Dickkopf-1 (Dkk-1) gene encodes an extracellular Wnt inhibitor that blocks the formation of signalling receptor complexes at the plasma membrane. Here, we report the serum levels of Dkk1 in colorectal cancer patients without any therapy. The levels were determined by enzyme-linked immunosorbent assay (ELISA) in 135 colon and 160 rectum cancer patients, as well as 90 healthy subjects. Data analyses were performed using SPSS software (SPSS 16, Chicago, IL). There were no significant differences among the groups for Dkk-1 (p=0.363). In conclusion, the present study did not confirm that serum Dkk-1 levels could have any diagnostic potential in colon and rectum cancers.
Insights
Serum Dickkopf-1 (Dkk-1) levels were investigated in colorectal cancer patients. This study found no significant difference in Dkk-1 levels, suggesting it lacks diagnostic potential for colon and rectum cancers.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The Wnt/b-catenin pathway is vital in development.
- Aberrant Wnt/b-catenin signaling is a key event in colon cancer.
- Dickkopf-1 (Dkk-1) is an extracellular Wnt inhibitor.
Purpose of the Study:
- To determine serum levels of Dkk-1 in colorectal cancer patients.
- To assess the diagnostic potential of serum Dkk-1 in colon and rectum cancers.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) was used to measure serum Dkk-1.
- The study included 135 colon cancer patients, 160 rectum cancer patients, and 90 healthy controls.
- Statistical analysis was performed using SPSS software.
Main Results:
- No significant differences in serum Dkk-1 levels were observed among colorectal cancer patients and healthy subjects (p=0.363).
Conclusions:
- The study did not confirm a diagnostic role for serum Dkk-1 in colon and rectum cancers.
- Serum Dkk-1 levels do not appear to be a reliable biomarker for diagnosing colorectal cancer in this cohort.
